|Trial||Total Screened||% Women Among Total Screened (n/N)||Screened Out∗||% Screened Out Among Screened (Number Screened Out/Number Women [or Men] Screened)||Enrolled†||% Women Among Total Enrolled (n/N)||PPR|
|Acute coronary syndrome #1 (prasugrel)||5,218||13,128||28 (5,218/18,346)||1,695||3,043||32 (1,695/5,218)||23||3,523||10,085||26 (3,523/13,608)||0.6|
|Atrial fibrillation #3 (rivaroxaban)||6,981||10,251||41||1,321||1,647||19||16||5,660||8,604||40||1.1|
|Atrial fibrillation #4 (apixaban)||7,507||13,491||36||1,091||1,706||15||13||6,416||11,785||35||1.0|
|Atrial fibrillation #5 (edoxaban tosylate)||9,896||15,601||39||1,856||2,536||19||16||8,040||13,065||38||1.1|
|Heart failure #3 (sacubitril/valsartan)||4,232||13,836||23||1,879||5,652||44||41||2,353‡||8,184‡||22||0.4|
Values are n unless otherwise indicated.
PPR = participation to prevalence ratio.
↵∗ Screen failures include participants who had a screening visit but were not randomized for various reasons.
↵† Participants who were randomized in the trial.
↵‡ This trial had run-in periods before a double-blind treatment period. The numbers indicate all participants eligible for the run-in period before randomization.